Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000723080 | SCV001765137 | uncertain significance | not provided | 2021-01-25 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002397501 | SCV002713513 | uncertain significance | Inborn genetic diseases | 2020-03-27 | criteria provided, single submitter | clinical testing | The p.P57L variant (also known as c.170C>T), located in coding exon 2 of the SCARB2 gene, results from a C to T substitution at nucleotide position 170. The proline at codon 57 is replaced by leucine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002477676 | SCV002775987 | uncertain significance | Action myoclonus-renal failure syndrome | 2022-05-20 | criteria provided, single submitter | clinical testing | |
Gharavi Laboratory, |
RCV000723080 | SCV000854211 | uncertain significance | not provided | 2018-09-16 | no assertion criteria provided | research |